Liposomal amphotericin B: clinical experience and perspectives (Q36140647)

12 August 2017

1 reference

title

Liposomal amphotericin B: clinical experience and perspectives (English)

1 reference

12 August 2017

1 reference

3

John R Perfect

1 reference

12 August 2017

Winter J Gibbs

1

1 reference

PubMed ID

15918775

12 August 2017

Richard H Drew

series ordinal

2

1 reference

PubMed ID

15918775

12 August 2017

language of work or name

1 reference

1 April 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

167-181

1 reference

12 August 2017

2

1 reference

The epidemiology of sepsis in the United States from 1979 through 2000

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

New approaches to the risk of Candida in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Voriconazole: therapeutic review of a new azole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Anidulafungin: review of a new echinocandin antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Micafungin: a therapeutic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Amphotericin B: spectrum and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Antifungal pharmacodynamics: review of the literature and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Recurrent blastomycosis of the central nervous system: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Disseminated Penicillium marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Amphotericin B in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Correlates of acute renal failure in patients receiving parenteral amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Risk factors for amphotericin B-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Risk factors for Amphotericin B-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.167

21 January 2018

Identifiers

DOI

10.1586/14787210.3.2.167

1 reference

12 August 2017

1 reference

PubMed ID

15918775